[1] HOU F,QI HY,YIN CH. Progress in drug treatment of chronic hepatitis C[J]. Chin J Med,2017,52(4):1-3.(in Chinese)侯斐,齐海宇,阴赪宏.慢性丙型肝炎的药物治疗进展[J].中国医刊,2017,52(4):1-3.
|
[2] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. The guideline of prevention and treatment for hepatitis C:A 2015 update[J]. J Clin Hepatol,2015,31(12):1961-1979.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.丙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1961-1979.
|
[3] KOHLI A,ALSHATI A,GEORGIE F,et al. Direct-acting antivirals for the treatment of chronic hepatitis C in patients with chronic kidney disease[J]. Therap Adv Gastroenterol,2016,9(6):887-897.
|
[4] WANG YB,XIE W. Chronic hepatitis C treatment:Hot spots,difficulties and problems that need to be solved[J]. Chin Clin Dr,2019,47(3):253-254.(in Chinese)王艳斌,谢雯.慢性丙型肝炎治疗:热点、难点及亟须解决的问题[J].中国临床医生杂志,2019,47(3):253-254.
|
[5] HONER Z,MAASOUMY B,MARRA F,et al. Drug-drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort[J]. Clin Infect Dis,2016,62(5):561-567.
|
[6] CHEN JH,ZENG Z,ZHANG XX. Efficacy and safety of combined directly acting antivirals for treatment of Chinese chronic hepatitis C patients in a real-world setting[J]. World J Gastroenterol,2017,23(22):4072-4079.
|
[7] ZHUANG LW,JI SB,ZHANG Y,et al. Efficacy and safety of Sofosbuvir combined with Velpatasvir in treatment of chronic hepatitis C and hepatitis C related liver cirrhosis patients with genotype 1~6:A Meta-analysis[J/CD]. Chin J Liver Dis:Electr Version,2019,11(2):30-36.(in Chinese)庄立伟,纪世博,张雨,等.Sofosbuvir联合Velpatasvir治疗1~6基因型慢性丙型肝炎和丙型肝炎肝硬化患者疗效及安全性Meta分析[J/CD].中国肝脏病杂志:电子版,2019,11(2):30-36.
|
[8] WANG JJ,WANG YB. Progress in direct antiviral drugs for hepatitis C virus[J]. Chin Clin Dr,2019,47(3):258-261.(in Chinese)王京京,王艳斌.丙型病毒性肝炎直接抗病毒药物研究进展[J].中国临床医生杂志,2019,47(3):258-261.
|
[9] YIN YX,MENG ZQ,LI XG,et al. Clinical effect of direct-acting antiviral agents for hepatitis C[J]. Chin Hepatol,2018,23(9):772-774.(in Chinese)尹艳霞,孟子强,李晓光.直接抗病毒药物治疗慢性丙型肝炎的临床疗效观察[J].肝脏,2018,23(9):772-774.
|
[10] AN ZY,SHENG QJ,DING Y,et al. Early efficacy and safety of direct-acting antivirals agents for the treatment of cirrhotic patients with hepatitis C[J]. Infect Dis Info,2016,29(2):81-84,96.(in Chinese)安子英,盛秋菊,丁洋,等.直接抗病毒药物治疗丙型肝炎肝硬化早期抗病毒疗效及安全性临床实践研究[J].传染病信息,2016,29(2):81-84,96.
|
[11] JI F,WANG W,DANG S,et al. Outcomes after sofobuvircontaining regimes for hepatitis C virus in patients with decompensated cirrhosis:A real-world study[J]. Infect Agent Cancer,2017,12:48.
|
[12] JI D,CHEN GF,WANG C,et al. Twelve-week ribavirinfree direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients[J]. Hepatol Int,2016,10(5):798-798.
|
[13] YANG Y,DANG SS. Safety of direct antiviral agents for treatment of hepatitis C virus infection[J]. World Chin J Dig,2017,25(8):659-669.(in Chinese)杨颖,党双锁.丙型肝炎直接抗病毒药物安全性应用进展[J].世界华人消化杂志,2017,25(8):659-669.
|
[14] BUNNELL KL,VIBHAKAR S,GLOWACKI RC,et al. Nephrotoxicity associated with concomitant use of ledipasvir-sofosbuvir and tenofovir in a patient with hepatitis C virus and human immunodeficiency virus coinfection[J]. Pharmacotherapy,2016,36(9):e148-e153.
|
[1] | Zhang Dan, Zhou Bo, Deng Yi, Wen Yu, Lu: JunYan, Wang JinXiang, Geng ZuoTao, Luo SuFeng, Ying YunYan, Wen DaiYan, Shi ChunJing, Pu GuangYu, Jiang Xin, Ma LanQing. Effect of fenofibrate on the diversity of intestinal flora in a mouse model of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(4): 829-834. doi: 10.3969/j.issn.1001-5256.2020.04.024 |
[2] | Chen Hao, Hao JianHeng, Li ZhenCheng, Xu HuiChao, Gao Yan, Miao YuChuan, Hao HuiQin, Liu Yang. Screening for differentially expressed genes in mice with autoimmune hepatitis and effect of saikosaponin-d on the expression of several differentially expressed genes[J]. Journal of Clinical Hepatology, 2020, 36(4): 840-846. doi: 10.3969/j.issn.1001-5256.2020.04.026 |
[3] | Tan Peng, Chen Hao, Wang AnKang, Qian BaoLin, Huang ZhiWei, Shi Hao, Gao Lin, Fu WenGuang. Effect of triptolide on fibrosis in a mouse model of cerulean-induced chronic pancreatitis[J]. Journal of Clinical Hepatology, 2020, 36(3): 641-645. doi: 10.3969/j.issn.1001-5256.2020.03.034 |
[4] | Du YiChao, Zhang Hao, Zhong FuRui, Cheng HuanLi, Lai Li, Qian BaoLin, Tan Peng, Xia XianMing, Fu WenGuang. Protective effect of pinocembrin in a mouse model of liver injury induced by acetaminophen[J]. Journal of Clinical Hepatology, 2020, 36(3): 608-611. doi: 10.3969/j.issn.1001-5256.2020.03.027 |
[5] | Yang ShuJuan, Guo YaLing, Fu Shan, He YingLi, Zhao YingRen, Tian Zhen. Role of the specific inhibitor of 5-lipoxygenase-activating protein MK886 in inhibiting alcoholic liver disease in mice[J]. Journal of Clinical Hepatology, 2019, 35(8): 1791-1796. doi: 10.3969/j.issn.1001-5256.2019.08.028 |
[6] | Zhao XiaoFang, Tang YouMing, Xu XinJie, Tang YanFang, Liu XuDong, Lu: Ping, Zhao ZhuangZhi. Effect on JNK1 gene silencing on the expression of high-molecular-weight adiponectin in mice with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2019, 35(10): 2257-2260. doi: 10.3969/j.issn.1001-5256.2019.10.025 |
[7] | Wang KaiXia, Zheng Chao, Zhang JingHao, Zhu XiaoJun, Wang Xuan, Kong XiaoNi, Gao YueQiu, Sun XueHua. Clinical effect of Qingre Jiedu Liangxue prescription in treatment of mice with acute-on-chronic liver failure and related mechanism[J]. Journal of Clinical Hepatology, 2019, 35(12): 2765-2771. doi: 10.3969/j.issn.1001-5256.2019.12.025 |
[8] | Bi YanZhen, Zhang QiuSheng, Fan Zeng, Yang YongHong, Zhang XiaoBei, Wang QuanQuan, Wang QuanYi, Wang YiBo, Duan ZhongPing, Chen Yu, Shu ZhenFeng, Si ChuanPing, Hong Feng. Effect of human liver-derived stem cells in prevention and treatment of alcoholic fatty liver disease in mice[J]. Journal of Clinical Hepatology, 2019, 35(3): 592-595. doi: 10.3969/j.issn.1001-5256.2019.03.027 |
[9] | Wang XiaoXiao, Zhao Jie, Li XiaoHe, Rao HuiYing, Wei Lai, Liu Feng. Value of second harmonic generation/two-photon excitation fluorescence in quantitative evaluation of liver fibrosis in mice with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2019, 35(8): 1786-1790. doi: 10.3969/j.issn.1001-5256.2019.08.027 |
[10] | Yang DaYin, Du YiChao, Tan Peng, Chen Hao, Qian BaoLin, Wang AnKang, Huang ShiYao, Fu WenGuang, Xia XianMing. Effect of Hic-5 gene knockout on NF-κB/p65 expression and CCl4-induced liver fibrosis degree in mice[J]. Journal of Clinical Hepatology, 2019, 35(11): 2483-2488. doi: 10.3969/j.issn.1001-5256.2019.11.019 |
[11] | Pan Jing, Pan WenTing, Wu LiHui. Expression and significance of Th22 cells and its functional factor interleukin-22 in mice with autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2018, 34(8): 1745-1749. doi: 10.3969/j.issn.1001-5256.2018.08.030 |
[12] | Shi HongBo, Shi HongLin, Zhang XiangYing, Chen DeXi, Duan ZhongPing, Ren Feng. Protective effect of autophagy in mice with acute liver injury induced by D- galactosamine / lipopolysaccharide and related mechanisms[J]. Journal of Clinical Hepatology, 2017, 33(2): 329-333. doi: 10.3969/j.issn.1001-5256.2017.02.027 |
[13] | Mai JingYin, Chen TianYang, Cheng Yang. Changes in microRNA expression profile in the liver of mice with nonalcoholic fatty liver disease induced by high-fat diet[J]. Journal of Clinical Hepatology, 2017, 33(12): 2372-2375. doi: 10.3969/j.issn.1001-5256.2017.12.023 |
[14] | Chen Jing, Liu XiaoYan, Yang HaoZhen, Huang Kun, Hu JinHua, Xin ShaoJie. Study on p-p38 expression and its significance in liver tissues of mice with acute liver failure and patients with HBV-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2015, 31(4): 556-559. doi: 10.3969/j.issn.1001-5256.2015.04.019 |
[15] | Yan XiaoMing, Zhang LiTing, Luo JingYi, Xiao Ping. Therapeutic effect of estradiol-pretreated human bone marrow mesenchymal stem cells on liver cirrhosis in mice[J]. Journal of Clinical Hepatology, 2015, 31(3): 424-430. doi: 10.3969/j.issn.1001-5256.2015.03.026 |
[16] | Peng Yuan, Tao YanYan, Huang Kai, Zhao Qiang, Liu ChengHai. Regulatory effect of poly I∶C on intrahepatic natural killer cells in mouse model of liver injury induced by carbon tetrachloride[J]. Journal of Clinical Hepatology, 2015, 31(12): 2077-2083. doi: 10.3969/j.issn.1001-5256.2015.12.022 |
[17] | Huang HaiYan, Xin YongNing, Jiang Man, Jin WenWen, Jiang XiangJun, Xuan ShiYing. Research advances in animal models of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2014, 30(9): 948-953. doi: 10.3969/j.issn.1001-5256.2014.09.028 |
[18] | Ye LiHong, Wang ChongKui, Yang Li, Gao HuiXia, Zhao ZhaoXia, Hou JunLiang, Dai ErHei. Effects of Ruangan Huajian granule on hepatic expression of α-SMA, TGFβ1, and COL-Ⅰ in C57 mice with experimental hepatic fibrosis [J]. Journal of Clinical Hepatology, 2012, 28(9): 685-688. |
[19] | Lou GuoHua, Liu YanNing, Yin ChunBen, Chen Feng, Jia ZhanSheng, Chen Zhi. Preliminary study of HCV mouse model induced by infectious HCV 2a plasmid[J]. Journal of Clinical Hepatology, 2011, 27(1): 72-75. |
[20] | Ye LiHong, Wang ChongKui, Tian YueYang, Xu Yi, Zheng HaoJie, Shao ShiXiang, Dai ErHei. Effect of Ruangan Huajian granule on hepatic expression of PDGF - B in C57 mice with experimental hepatic fibrosis[J]. Journal of Clinical Hepatology, 2011, 27(10): 1047-1050. |